Surya Pharma to set up 500 healthcare stores

Surya Pharmaceutical Limited plans to set up more than 500 healthcare & Pharma retail stores under the brand name Viva in the next three years. It would set up 100 stores in Delhi and the NCR by March 2010 and follow this up by more stores in North India and other parts of the country. The company is targeting to be a leading retailer offering a comprehensive and integrated mix of related products. It is very soon launching a chain of chemist and well ness outlets in North India under the “VIVA” brand and plans to expand to locations across India in the next 3 years.
“The presence of a huge spurious drug market along with increasing number of lifestyle and stress-related ailments prompted us to foray into healthcare retail,” said Mr Rajiv Goyal, Chairman & Managing Director, Surya Pharmaceutical Limited. The total capital outlay of about Rs 2.5 billion approx in next 3 years is proposed to be met through a combination of Promoters, Equity, Venture Capital, Private Equity and borrowings from Banks.
The stores have different formats according to the locations where they are situated. Our stores ranging from 150 sq ft area to 1000 sq ft area would sell medicines as well as health and fitness products. The retail business would operate under the company-owned initially and the franchise format later on.
Surya Pharmaceutical Limited started its operations in 1992 in Panchkula followed by two facilities in Baddi and another in Banur in 1995 and 2000 respectively. The pharmaceutical business has been expanded by setting up Greenfield mint derivatives projects at Baddi in Himachal Pradesh and Sambha in Jammu and Kashmir.
Surya Pharmaceutical Limited has grown from a Rs 50 million enterprise in 1993 to Rs 5 billion in 2008 and is expected to touch Rs 15 billion by 2011. With this projected turnover, the company has a pan-global presence with business interests in about 70 countries across the globe. The company plans to expand its horizons fast and is preparing to enter European & American Pharmaceutical markets by 2011. By 2011, Surya Group expects to achieve a group turnover exceeding Rs 20 billion.
Besides growing organically through y.o.y growth of 40-45%, Surya Pharmaceutical Ltd proposes to grow inorganically also through proposed acquisitions in overseas and domestic markets. Currently the company is negotiating with a company in Germany and another in India for possible acquisitions.
“We are constantly striving to fulfill our three corporate principles of sustaining growth in our key businesses, setting leadership standards through continuous training and development and empowering lives in the areas where we are present,” added Mr Goyal.

Hash biotech selected by UN to promote spirulina

To realize its ambition of a world free of malnutrition and hunger, IIMSAM joined hands with Hash Biotech Labs Private Limited from the Republic of India. Hash Biotech Labs Private Limited which has been declared as an Official Working Partner and Technology Facilitator by the IIMSAM, shall help the organization carry and secure its mandate in India and South Asia- a region that has the worst malnutrition statistics in the world.
Spirulina that was declared as the best food for the future by the United Nations World Food Conference in the year 1974 holds tremendous potential to eradicate malnutrition, achieve food security and bridge health divide.
Hash Biotech Labs is part of the Hash Group of Companies which is led by young entrepreneur Mr. Vikrant Sandal who firmly believes that businesses have to play a larger and leading role in the 21st century sustainable development agenda. The young scientific team of the Hash Biotech Labs works under the able guidance of world renowned scientist Dr. Surendra Singh who has done significant and exemplary work in the field of micro-algal research.
IIMSAM along with the Hash Biotech Labs and Kanwaljit Sandal Foundation is also developing an IIMSAM-KSF Model for Grassroots Development which is a self-sustainable micro-entrepreneurship development programme which has a specific relevance for the developing countries.
Initially to be launched in India and South Asia, the programme shall soon spread to whole of the developing world.
(H.E. Amb. Manish Uprety offering prayers and homage to Late. Mr. Kanwaljit Sandal in Dasuya, Hoshirapur, India)
(Spirulina Educational Centre of Hash Biotech Labs in Dasuya, Hoshiyarpur, Punjab, India)
Besides providing free state of the art scientific technology for Spirulina cultivation to the poor farmers, women and self help groups; the programme shall encompass a unique Spirulina-Buy Back Guarantee arrangement which shall safeguard the socio-economic interests of the farmers.
Spirulina cultivation has specific relevance for the developing countries as the size of land holdings is continually decreasing with the years
leading to disempowerment and loss of capabilities of farmers and small land holding dwellers.
IIMSAM not only aspires to make Spirulina a key driver to eradicate malnutrition, achieve food security and bridge the health divide but also wants to establish lasting capacities and capabilities at the grassroots that initiate a self-sustainable empowerment process.
IIMSAM specifically chose Hash Laboratories as the Spirulina facilities of the organization are in Dasuya, Hoshiyarpur District of Punjab in India which has been declared as a backward. Not only the very facilities shall provide local employment opportunities but would also establish the district as a leading bio-technological hub in the country and the world. IIMSAM recognizes the relevance of Spirulina to eradicate malnutrition and to achieve the United Nations Millennium Development Goals. Our hybrid approach that has United Nations Global Compact as the bedrock recognizes the important role that businesses can play to achieve common goals; and our initiatives have a special priority for the marginalized.